Received Mar 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 4N222 | IM |
patient that accidentally received IM versus subcutaneous; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 67-year-old patient who received MMR (Priorix) (batch number 4N222, expiry date 13-SEP-2026) for prophylaxis. On 14-MAR-2025, the patient received Priorix (intramuscular). On 14-MAR-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: patient that accidentally received IM versus subcutaneous). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 14-MAR-2025 Pharmacist reported they changed to the Priorix, the MMR-II, and did not realize that Priorix is preferred to be subcutaneously administration versus IM, which is the other manufacturer. So, they wanted to see if there was any risk that they need to be aware of, for they have a patient that accidentally received IM versus subcutaneous. The vaccine which is preferred to be subcutaneously administered to the patient intramuscularly, which led to subcutaneous injection formulation administered by other route.